ETM Experimental and Therapeutic Medicine 1792-0981 1792-1015 D.A. Spandidos 10.3892/etm.2019.7509 ETM-0-0-7509 Articles Association of Helicobacter pylori infection with metabolic syndrome in aged Chinese females YuYingying 1 CaiJianting 2 SongZhenya 1 WangJinghua 1 WuLingyan 1 Department of General Practice, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310000, P.R. China Department of Gastroenterology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310000, P.R. China Correspondence to: Dr Jianting Cai, Department of Gastroenterology, The Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou, Zhejiang 310009, P.R. China, E-mail: dleowa@zju.edu.cn 06 2019 19 04 2019 17 6 4403 4408 22102018 13032019 Copyright: © Yu et al. 2019 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

The association between Helicobacter pylori (H. pylori) infection and metabolic syndrome (MetS) determined in different cohorts from different countries is currently inconclusive. In the majority of previous studies, H. pylori infection was diagnosed based on the presence of H. pylori IgG antibody in the serum. However, to the best of our knowledge, only few studies have investigated the association between H. pylori infection and MetS using the urea breath test (UBT) as a diagnostic tool. The present study was performed with the aim of providing a detailed analysis of the association between H. pylori infection, as diagnosed by the UBT method, and MetS in a large community from Zhejiang province in eastern China. The results indicated that H. pylori infection increases the risk of MetS in the aged female population.

 Helicobacter pylori metabolic syndrome insulin resistance 13C-urea breath test Chinese aged women Introduction

Metabolic syndrome (MetS) comprises a group of metabolic abnormalities, including central obesity, impaired glucose tolerance, insulin resistance (IR), lipid metabolism disorders and hypertension, which markedly increase the risk of diabetes mellitus and cardio-cerebrovascular disease (1–3). Approximately one-quarter of the population worldwide have been reported to suffer from MetS (2). Chronic inflammation was previously suggested to be implicated in MetS (4).

Helicobacter pylori (H. pylori) infection is one of the most common infections globally, affecting >50% of the world's population, particularly in developing countries. Its prevalence varies across different cohorts with differences in age and developmental status (5,6). H. pylori infection may cause chronic gastritis, peptic ulcers and gastric cancer (7–9). More recently, H. pylori gastritis was considered as an infectious disease (10). H. pylori infection has been indicated to increase systemic inflammation by producing inflammatory factors, including C-reactive protein (CRP), tumor necrosis factor-α, interferon-γ and interleukin-1, −6 and −8, and these factors were confirmed to be involved in the pathogenesis of IR (11,12). In addition to gastrointestinal infections, H. pylori has also been reported to be associated with various extra-intestinal diseases, including MetS (13–20).

At present, the association between H. pylori infection and MetS determined in different cohorts of different countries remains inconclusive (17,20–32). In the majority of those studies, H. pylori infection was diagnosed based on the presence of H. pylori IgG antibody in the serum (29–31); however, serum IgG may persist after H. pylori is eradicated and may therefore not reflect the current infection status (33). The 13C-urea breath test (UBT) is a non-invasive method for detecting current H. pylori infection. The sensitivity and specificity of the UBT are ~0.96 [95% confidence interval (CI): 0.95–0.97] and 0.93 (95% CI: 0.91–0.94), respectively (34). While it may be assumed that only current infection is able to cause systemic inflammatory reactions, few studies have investigated the association between H. pylori infection and MetS using UBT as the diagnostic method, to the best of our knowledge.

Therefore, given the diversity of the incidence of H. pylori infection across different countries and the controversial results of the studies investigating the association between H. pylori infection and MetS, particularly in East Asia, it is crucial to further investigate this association in a large population. The aim of the present study was to provide a detailed analysis of the association between H. pylori infection, as diagnosed by UBT, and MetS in a large community from Zhejiang province in eastern China.

 Materials and methods <sec> <title>Study participants

Participants who voluntarily underwent a general health screening between January 2014 and December 2015 were recruited at the International Health Care Center of the Second Affiliated Hospital of Zhejiang University School of Medicine (Hangzhou, China). Participants with any of the following characteristics were excluded from the study: i) History of gastric surgery; ii) history of anti-H. pylori therapy; iii) use of antibiotics, proton pump inhibitors, H2 blockers or bismuth within the previous 4 weeks; iv) severe mental or neurological disorders; v) history of cancer(s). All subjects underwent a detailed physical examination, including UBT detection of H. pylori infection.

 Diagnosis of H. pylori infection

After fasting for at least 2 h, all of the participants underwent a 13C-UBT (Richen-Force, Beijing, China) for the detection of H. pylori infection. After collecting the baseline breath sample, the participants ingested a 13C-urea reagent dissolved in water. The second breath sample was collected and analyzed after 30 min. A delta over baseline value ≥4.0 indicated a positive result for H. pylori infection.

 Definitions of the study variables

For each participant, age, sex, weight, height, body mass index (BMI) and waist circumference were recorded. Blood pressure was measured after at least 10 min of rest. Waist circumference was measured with a measuring tape while standing, midway between the lowest rib and the iliac crest. The BMI was calculated as follows: Weight (kg)/[height (m)]2.

Information on the history of smoking and alcohol consumption, as well as the medical history, including hypertension, hyperlipidemia and/or diabetes, was also collected using a questionnaire. The questionnaire also included the history of the present illness, previous diagnoses of H. pylori infection, history of anti-H. pylori therapy and confirmation of eradication after treatment. If the questionnaire was incomplete, the patient was contacted to ensure for integrity of the data.

Laboratory examinations were performed after a 10-h fast, including white blood cell (WBC) count, hemoglobin (Hb), platelet count, high-sensitivity (HS)-CRP, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol (HDL-C), triglyceride (TG), total bilirubin, alanine aminotransferase (ALT), γ-glutamyl transpeptidase, aspartate aminotransferase (AST), fasting plasma glucose, glycosylated Hb (HbA1c), 2-h postprandial plasma glucose, fasting insulin, blood urea nitrogen, creatinine (Cr), uric acid (UA), homocysteic acid (HCY) and serum cystatin C (CYSC).

The identification of individuals with MetS was based on the definition of the International Diabetes Federation (35) as follows: i) Central obesity (waist circumference, ≥90 and ≥80 cm in Chinese males and females, respectively); ii) a combination of any of the following four indicators: TG level increased to >150 mg/dl (1.7 mmol/l), or treated accordingly; HDL-C level decreased to <40 mg/dl (0.9 mmol/l) in males and <50 mg/dl (1.1 mmol/l) in females, or the patient receiving corresponding treatment; systolic blood pressure ≥130 or diastolic blood pressure ≥85 mmHg, or treated accordingly, or previous diagnosis of hypertension; and fasting plasma glucose level increased to ≥100 mg/dl (5.6 mmol/l), or previous diagnosis of type 2 diabetes mellitus, or the patient receiving corresponding treatment.

IR is generally considered to be the most important pathophysiological basis for MetS. The homeostasis model assessment (HOMA) score may be used to estimate IR, which is defined as follows: [Fasting plasma insulin (mU/l) × fasting plasma glucose (mmol/l)]/22.5. A high HOMA-IR score denotes low insulin sensitivity and IR (36). Based on a previous study (17), three cut-off values of the HOMA-IR index (2, 2.5 and 3) were adopted to evaluate IR.

 Statistical analysis

The statistical analysis was performed using IBM-SPSS 24.0.0.0 software (IBM Corp.) and Python. Wilcoxon's rank-sum test was used to evaluate differences between groups for quantitative data, and the Chi-squared test was used for qualitative data. All P-values were based on a two-sided test of statistical significance. P<0.05 was considered to indicate a statistically significant difference. The optimal cut-off point of age was calculated using the maximization of Youden's index (sensitivity+specificity-1) in the receiver operating curve analysis. The association between H. pylori status and MetS characteristics was evaluated by a multivariate logistic regression (LR) analysis model following adjustment for age, sex, alcohol consumption, smoking, WBC count, HS-CRP, ALT, AST, HbA1C, HCY, CYSC, Cr and UA levels. The patients were further stratified into subgroups based on age and sex.

 Results <sec> <title>Clinical and demographic characteristics

In the present study, 5,884 participants were included after screening of a total of 10,602 subjects (Fig. 1). The study subjects had a mean age of 46.81±10.13 years and 2,053 (34.9%) were female. A total of 1,265 (21.5%) had MetS, with a different percentage among males and females (24.8 vs. 15.3%, respectively; P<0.001). In addition, the prevalence of MetS was identified to increase with age, particularly in females.

The overall prevalence of H. pylori infection in this cohort was 46%, and it was higher in male compared with female patients (47.1 vs. 43.9%, respectively; P=0.023), however, it did not exhibit any differences across different age groups.

A statistically significant difference in the presence of H. pylori was observed between subjects with and those without MetS (50.4 vs. 44.8%, respectively; P<0.001; Table I).

 Overall, age and sex subgroup analyses for the risk of MetS associated with H. Pylori infection

A multivariate LR model was constructed for predicting MetS by considering the H. pylori infection status and other potential covariates, including sex, age and HOMA-IR. It was observed that H. pylori infection was a significant risk factor contributing to the prediction of MetS with a broad-line risk of 1.2 (95% CI: 1.02–1.36, P=0.028; Table II). Subsequently, a receiver operating characteristic curve analysis on age was performed to segment participants, which indicated the age of 50 years as an optimal threshold (i.e., maximizing Youden's index; Table III). It was also used to differentiate the MetS distribution between subjects with or without H. pylori infection. Furthermore, A multivariate LR model analyses revealed that H. pylori infection was a significant risk factor for MetS in male participants aged <50 years and in female participants aged ≥50 years (Table IV).

 Multivariate LR analysis of H. pylori infection and other factors with MetS

A multivariate LR analysis was performed to determine the risk of MetS associated with the H. pylori infection status and other metabolic-associated parameters, which were not direct variables in defining MetS, including WBC count, HS-CRP, ALT, AST, HbA1c, HCY, CYSC, Cr and UA. It was observed that H. pylori infection, age, sex, HS-CRP, HbA1c, UA and Cr were also positively associated with MetS (Table V). When stratifying participants into different gender groups and different age groups, similar patterns among contributors for predicting MetS were revealed. It was noted that, when the subjects were stratified by sex and further by age, H. pylori infection was significantly associated with MetS in female patients aged ≥50 years [odds ratio (OR)=1.29, 95% CI: 1.09–1.91; Table VI].

 Discussion

The present study investigated the prevalence of H. pylori infection in subjects with MetS, and further explored the association of H. pylori infection and other factors with MetS. A significant difference was identified in the presence of H. pylori infection between subjects with and those without MetS (50.4 vs. 44.8%, respectively; P<0.001). In a multivariate LR analysis, H. pylori infection was determined to be significantly associated with MetS in female patients aged ≥50 years.

Several studies have identified H. pylori infection as a risk factor for MetS (17,20–25). Chen et al (17), reported that the prevalence of MetS was higher among H. pylori-positive individuals of either gender in a Chinese adult cohort. Upala et al (21) demonstrated that H. pylori infection was positively associated with IR using a meta-analysis. Yang and Xuan (25) indicated that elderly patients (aged 73.19±11.03 years) with H. pylori infection had a higher BMI and fasting glucose levels and a higher incidence of MetS. Furthermore, certain studies suggested that H. pylori infection has a causative association with MetS through pathophysiological analysis (26–28). By contrast, other studies failed to prove this association (29–32). For instance, Naja et al (31) reported no suggested association of H. pylori infection with IR or MetS in Lebanese adults. Similarly, Tamura et al (32), identified no association between H. pylori infection and diabetes in a Japanese population.

In addition to national and regional factors, these inconsistent results may be due to the different screening methods for H. pylori infection among different studies. H. pylori infection is diagnosed on the basis of clinical and laboratory findings, as well as microbiological and histopathological examinations following endoscopy. Shin et al (37), observed that MetS was more closely associated with histological positivity for H. pylori (adjusted OR=1.26; 95% CI: 1.08–1.48) rather than serological positivity (adjusted OR=1.12, 95% CI: 0.95–1.32). This conclusion was attributed to the fact that serological positivity for H. pylori does not necessarily indicate current infection. Only few studies have been performed to assess the effects of H. pylori infection on MetS in Chinese populations, and most of those are based on the detection of IgG antibody in the serum. Although Chen et al (17) used 13C-UBT to demonstrate that H. pylori infection is positively associated with MetS, the systemic association among MetS, H. pylori infection and other variables has remained to be elucidated.

In the present study, a different prevalence of H. pylori infection was observed between male and female subjects (47.1 vs. 43.9%, respectively; P=0.023), whereas Chen et al (17) reported a similar prevalence in either gender (20%) in an adult population from Taiwan. In addition, there was no difference in the prevalence of H. pylori infection among different age groups; however, they reported an increase in prevalence with advancing age in males and females (17). Those results indicate a different prevalence (also between the two sexes) of MetS and H. pylori infection across the Chinese population, suggesting that different measures have to be taken accordingly. In addition, the present study also observed a difference in the prevalence of MetS between sexes (24.8 vs. 15.3% in male and female subjects, respectively), consistently with the results of a more recent study (38).

This association was further investigated by stratifying the subjects into males and females, and into different age groups. An increased significance was observed in aged females, which was consistent with a previous study reporting that H. pylori infection was a predictor of MetS in elderly patients (aged 73.19±11.03 years) (25). Although in the present study, H. pylori infection was significantly associated with MetS, it was observed that H. pylori infection per se was only a weak predictor of MetS (accuracy, 65%) regardless of sex and age (all these models achieved an accuracy of ~65%). Furthermore, H. pylori infection was not the major contributor in the LR model compared with other metabolism-associated parameters, but it may be an important contributor to MetS when combined with other factors. Due to the higher incidence of hyperlipidemia, hyperglycemia or hypertension among individuals aged >50 years, H. pylori infection has a greater impact in this population. In addition, it has been demonstrated that post-menopausal females have significantly reduced estrogen levels, reduced resistance to inflammatory reactions and increased levels of inflammatory factors (39,40), which may explain for the more pronounced inflammatory response of aged females to H. pylori infection compared with males.

The health check-up population at our center mainly comprised residents from Zhejiang province, so the economic level is expected not to differ significantly. In fact, the questionnaire included queries associated with socioeconomic conditions and eating habits. However, a previous statistical analysis indicated that their impact was not significant, so they were not included in the present study.

Of note, the present study had certain limitations. First, the subjects were recruited from a single center. Second, the present study was an observational study, and conclusions may only be drawn regarding the association between H. pylori infection and other factors with MetS.

In conclusion, H. pylori infection increases the risk of MetS in aged females. However, these observations are inconsistent across different cohorts, which warrants further investigation by prospective or biochemical studies. If confirmed, eradication of H. pylori infection may be of therapeutic value for MetS.

 Acknowledgements

The authors would like to thank Dr Bin Ju (Department of Epidemiology of Zhejiang University) for his advice regarding statistics throughout the project.

 Funding

The present study was supported by the Zhejiang Provincial Natural Science Foundation of China (grant no. LGF19H030016), the Education Department of Zhejiang Province (grant no. Y201636053), and the Zhejiang Provincial Medical Scientific and Technological Projects (grant nos. 2017KY387 and 2018KY413).

 Availability of data and materials

All the datasets generated and analyzed in the present study are included in this published article.

 Authors' contributions

YY and JC contributed to the literature search and the writing of the manuscript; JW and LW contributed to data collection and analysis; ZS designed the study.

 Ethics approval and consent to participate

All of the participants provided written informed consent prior to the examination. The present study was reviewed and approved by the Ethics Committee of the 2nd Affiliated Hospital, School of Medicine, Zhejiang University (Hangzhou, China; no. 2013-218).

 Patient consent for publication

Not applicable.

 Competing interests

The authors declare no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

 Abbreviations H. pylori

Helicobacter pylori

 MetS

metabolic syndrome

 BMI

body mass index

 WBC

white blood cell

 Hb

hemoglobin

 ALT

alanine aminotransferase

 AST

aspartate aminotransferase

 Cr

creatinine

 UA

uric acid

 HCY

homocysteic acid

 CYSC

serum cystatin C

 HS-CRP

high-sensitivity C-reactive protein

 HbA1c

glycosylated Hb

 HOMA-IR

homeostasis model assessment of insulin resistance

 HDL-C

high-density lipoprotein cholesterol

 TG

triglyceride

 95% CI

95% confidence interval

 OR

odds ratio

 References SamsonSLGarberAJMetabolic syndromeEndocrinol Metab Clin North Am43123201410.1016/j.ecl.2013.09.00924582089 GiudiceACrispoAMassimilianoGD'ArenaGTecceMFGrimaldiMAmoreAEspositoEMontellaMMetabolic syndrome, insulin resistance, circadian disruption, antioxidants and pancreatic carcinoma: An overviewJ Gastrointestin Liver Dis237377201424689100 HoffmanELVonWaldTHansenKThe metabolic syndromeS D Med924282015 FestaAD'AgostinoRJrHowardGMykkänenLTracyRPHaffnerSMChronic subclinical inflammation as part of the insulin resistance syndrome: The insulin resistance atherosclerosis study (IRAS)Circulation1024247200010.1161/01.CIR.102.1.4210880413 SuerbaumSMichettiPHelicobacter pylori infectionN Engl J Med34711751186200210.1056/NEJMra02054212374879 McCollKEClinical practice. Helicobacter pylori infectionN Engl J Med36215971604201010.1056/NEJMcp100111020427808 QadriQRasoolRGulzarGMNaqashSShahZAH. pylori infection, inflammation and gastric cancerJ Gastrointest Cancer45126132201410.1007/s12029-014-9583-124557546 AthertonJCThe pathogenesis of Helicobacter pylori-induced gastro-duodenal diseasesAnnu Rev Pathol16396200610.1146/annurev.pathol.1.110304.10012518039108 LeeYCChenTHChiuHMShunCTChiangHLiuTYWuMSLinJTThe benefit of mass eradication of Helicobacter pylori infection: A community-based study of gastric cancer preventionGut62676682201310.1136/gutjnl-2012-30224022698649 MalfertheinerPMegraudFO'MorainCAGisbertJPKuipersEJAxonATBazzoliFGasbarriniAAthertonJGrahamDYManagement of Helicobacter pylori infection-the Maastricht V/Florence Consensus ReportGut66630201710.1136/gutjnl-2016-31228827707777 OshimaTOzonoRYanoYOishiYTeragawaHHigashiYYoshizumiMKambeMAssociation of Helicobacter pylori infection with systemic inflammation and endothelial dysfunction in healthy male subjectsJ Am Coll Cardiol4512191222200510.1016/j.jacc.2005.01.01915837252 FranceschiFAnnalisaTTeresaDRGiovannaDIaniroGFrancoSVivianaGValentinaTRiccardoLLAntonioGRole of Helicobacter pylori infection on nutrition and metabolismWorld J Gastroenterol201280912817201410.3748/wjg.v20.i36.1280925278679 KyburzAMullerAHelicobacter pylori and extragastric diseasesCurr Top Microbiol Immunol400325347201728124160 GoniEFranceschiFHelicobacter pylori and extragastric diseasesHelicobacter21(Suppl 1)S45S48201610.1111/hel.12340 AlbakerWIHelicobacter pylori infection and its relationship to metabolic syndrome: Is it a myth or fact?Saudi J Gastroenterol17165169201110.4103/1319-3767.8037721546717 ChenLWChienCYYangKJKuoSFChenCHChienRNHelicobacter pylori infection increases insulin resistance and metabolic syndrome in residents younger than 50 years old: A community-based studyPLoS One10e0128671201510.1371/journal.pone.012867126020514 ChenTPHungHFChenMKLaiHHHsuWFHuangKCYangKCHelicobacter pylori infection is positively associated with metabolic syndrome in taiwanese adults: A cross-sectional studyHelicobacter20184191201510.1111/hel.1219025582223 Işıktaş SayılarEÇelikBDumluŞRelationship between Helicobacter pylori infection and metabolic syndromeTurk J Gastroenterol26468473201510.5152/tjg.2015.019726510087 KokluHKokluSCinarHHelicobacter pylori and metabolic syndromeTurk J Gastroenterol27201201610.5152/tjg.2015.15050926853791 VafaeimaneshJBagherzadehMMirzaeiAParhamMNorouziniaMVafaeeREffect of Helicobacter pylori on metabolic syndrome parameters in diabetic patientsGastroenterol Hepatol Bed Bench9(Suppl 1)S36S41201628224026 UpalaSJaruvongvanichVRiangwiwatTJaruvongvanichSSanguankeoAAssociation between Helicobacter pylori infection and metabolic syndrome: A systematic review and meta-analysisJ Dig Dis17433440201610.1111/1751-2980.1236727273478 PolyzosSAKountourasJNovel advances in the association between helicobacter pylori infection, metabolic syndrome, and related morbidityHelicobacter20405409201510.1111/hel.1222825854149 KayarYPamukçuÖEroğluHKalkan ErolKIlhanAKocamanORelationship between Helicobacter pylori infections in diabetic patients and inflammations, metabolic syndrome, and complicationsInt J Chronic Dis2015290128201526464868 LuLJHaoNBLiuJJLiXWangRLCorrelation between Helicobacter pylori infection and metabolic abnormality in general population: A cross-sectional studyGastroenterol Res Pract20187410801201810.1155/2018/741080129743888 YangWXuanCInfluence of Helicobacter pylori infection on metabolic syndrome in old chinese peopleGastroenterol Res Pract20166951264201610.1155/2016/695126427429613 AndoTIshikawaTTakagiTImamotoEKishimotoEOkajimaAUchiyamaKHandaOYagiNKokuraSImpact of Helicobacter pylori eradication on circulating adiponectin in humansHelicobacter18158164201310.1111/hel.1202823167259 de LuisDAGarcia AvelloALasuncionMAAllerRMartin de ArgilaCBoixeda de MiquelDde la CalleHImprovement in lipid and haemostasis patterns after Helicobacter pylori infection eradication in type 1 diabetic patientsClin Nutr18227231199910.1016/S0261-5614(99)80074-010578022 GenRDemirMAtasevenHEffect of Helicobacter pylori eradication on insulin resistance, serum lipids and low-grade inflammationSouth Med J103190196201010.1097/SMJ.0b013e3181cf373f20134372 DevarajSRosensonRSJialalIMetabolic syndrome: An appraisal of the pro-inflammatory and procoagulant statusEndocrinol Metab Clin North Am33431453200410.1016/j.ecl.2004.03.00815158528 GillumRFInfection with Helicobacter pylori, coronary heart disease, cardiovascular risk factors, and systemic inflammation: The third national health and nutrition examination surveyJ Natl Med Assoc9614701476200415586651 NajaFNasreddineLHwallaNMoghamesPShoaibHFatfatMSibaiAGali-MuhtasibHAssociation of H. pylori infection with insulin resistance and metabolic syndrome among lebanese adultsHelicobacter17444451201210.1111/j.1523-5378.2012.00970.x23066847 TamuraTMoritaEKawaiSSasakabeTSugimotoYFukudaNSumaSNakagawaHOkadaRHishidaANo association between Helicobacter pylori infection and diabetes mellitus among a general Japanese population: A cross-sectional studySpringerplus4602201510.1186/s40064-015-1371-226543737 MiernykKMBrudenDLBruceMGMcMahonBJHennessyTWPetersHVHurlburtDASaccoFParkinsonAJDynamics of Helicobacter pylori-specific immunoglobulin G for 2 years after successful eradication of Helicobacter pylori infection in an American Indian and Alaska native populationClin Vaccine Immunol148586200710.1128/CVI.00253-0617079433 FerwanaMAbdulmajeedIAlhajiahmedAMadaniWFirwanaBHasanRAltayarOLimburgPJMuradMHKnawyBAccuracy of urea breath test in Helicobacter pylori infection: Meta-analysisWorld J Gastroenterol2113051314201510.3748/wjg.v21.i4.130525632206 AlbertiKGZimmetPShawJIDF Epidemiology Task Force Consensus GroupThe metabolic syndrome-a new worldwide definitionLancet36610591062200510.1016/S0140-6736(05)67402-816182882 Gayoso-DizPOtero-GonzálezARodriguez-AlvarezMXGudeFGarcíaFDe FranciscoAQuintelaAGInsulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: Effect of gender and age: EPIRCE cross-sectional studyBMC Endocr Disord1347201310.1186/1472-6823-13-4724131857 ShinDWKwonHTKangJMParkJHChoiHCParkMSParkMSParkSMSonKYChoBAssociation between metabolic syndrome and Helicobacter pylori infection diagnosed by histologic status and serological statusJ Clin Gastroenterol46840845201210.1097/MCG.0b013e318252247723064216 RefaeliRChodickGHajSGorenSShalevVMuhsenKRelationships of H. pylori infection and its related gastroduodenal morbidity with metabolic syndrome: A large cross-sectional studySci Rep84088201810.1038/s41598-018-22198-929511278 Figueroa-VegaNMoreno-FríasCMalacaraJMAlterations in adhesion molecules, pro-inflammatory cytokines and cell-derived microparticles contribute to intima-media thickness and symptoms in postmenopausal womenPLoS One10e0120990201510.1371/journal.pone.012099025993480 Taleb-BelkadiOChaibHZemourLFatahAChafiBMekkiKLipid profile, inflammation, and oxidative status in peri- and postmenopausal womenGynecol Endocrinol32982985201610.1080/09513590.2016.121425727558905

Flow chart depicting the enrolment of subjects in the present study.

Demographic characteristics of subjects with or without MetS.

MetS
Features Yes No P-value
Sex (female%) 315 (24.9) 1738 (32.6) <0.001
Age (years) 50.9±9.9 46.3±10.3 <0.001
Height (cm) 167.8±8.0 165.7±7.8 <0.001
Weight (kg) 75.8±10.5 63.8±10.2 <0.001
BMI (kg2/m2) 26.8±2.6 23.2±2.7 <0.001
Waist (cm) 94.1±6.7 82.2±8.3 <0.001
WBC (×109/l) 6.51±1.6 6.1±1.6 <0.001
Hb (g/l) 150.5±14.5 144.7±16.1 <0.001
PLT(×109/l) 214.0±55.7 212.5±53.6 0.390
T-BiL (µmol/l) 13.7±5.3 13.7±5.7 0.790
ALT (U/l) 34.5±26.99 23.5±23.1 <0.001
GGTP (U/l) 56.8±54.4 34.0±38.99 <0.001
AST (U/l) 27.0±12.7 22.9±13.2 <0.001
Hs-CRP (mg/l) 2.1±3.1 1.2±2.4 <0.001
BUN (mmol/l) 5.3±1.2 4.98±1.2 <0.001
Cr (mmol/l) 65.2±14.0 63.1±13.97 <0.001
UA (µmol/l) 387.2±90.9 336.3±86.8 <0.001
HCY (µmol/l) 11.2±5.3 10.5±5.2 <0.001
CYS (mg/l) 0.95±0.2 0.9±0.2 <0.001
TC (mmol/l) 5.2±1.1 4.9±0.9 <0.001
TG (mmol/l) 2.7±2.3 1.4±1.3 <0.001
LDL (mmol/l) 2.9±0.8 2.8±0.7 <0.001
HDL (mmol/l) 1.07±0.3 1.2±0.3 <0.001
FBG (mg/dl) 5.9±1.7 5.0±0.8 <0.001
HbA1c (%) 7.4±1.1 6.8±0.7 <0.001
PBG (mg/dl) 9.0±4.1 6.5±2.5 <0.001
FINS (pmol/l) 100.8±51.9 63.6±35.9 <0.001
DBP (mmHg) 83.4±10.6 74.3±11.3 <0.001
SBP (mmHg) 136.7±16.6 121.6±16.9 <0.001
H. pylori infection (%) 637 (50.4) 2068 (44.8) <0.001
HOMA-IR 3.8±2.3 2.1±1.5 <0.001
>2 (%) 1057 (87) 1958 (42.8) <0.001
>2.5 (%) 888 (71.5) 1180 (25.8) <0.001
>3 (%) 711 (57.2) 689 (15.3) <0.001
Carotid atherosclerosis (%) 441 (37.1) 949 (22.8) <0.001
Diabetes (%) 201 (15.9) 174 (3.8) <0.001
Fatty liver (%) 1037 (82) 1520 (32.9) <0.001
Drinking (%) 700 (55.3) 2055 (44.5) <0.001
Smoking (%) 528 (42.1) 1429 (30.9) <0.001
Hypertension (%) 416 (32.9) 499 (10.8) <0.001
Hyperlipidemia (%) 70 (5.5) 53 (1.1) <0.001

H. pylori, Helicobacter pylori; MetS, metabolic syndrome; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; WBC, white blood cell; Hb, hemoglobin; PLT, platelets; T-BiL, total bilirubin; BUN, blood urea nitrogen; Cr, creatinine; UA, uric acid; HCY, homocysteic acid; CYSC, serum cystatin C; ALT, alanine aminotransferase; GGTP, γ-glutamyltranspeptidase; AST, aspartate aminotransferase; HS-CRP, high-sensitivity C-reactive protein; FPG, fasting blood glucose; PBG, 2-hour postprandial blood glucose; FINS, fasting insulin; HbA1c, glycosylated hemoglobin; HOMA-IR, homeostasis model assessment of insulin resistance; TC, total cholesterol; LDL-C, low-density lipoprotein; HDL-C, high-density lipoprotein; TG, triglyceride.

LR analysis of MetS risk associated with H. pylori and other factors.

Variables OR [95% CI] P-value
H. pylori infection 1.21 [1.02–1.36] 0.028
HOMA-IR 2.13 [1.98–2.20] <0.001
Age (years) 1.11 [1.04–1.16] <0.001
Gender 1.54 [1.27–1.75] <0.001

H. pylori, Helicobacter pylori; HOMA-IR, homeostasis model assessment of insulin resistance; 95% CI, 95% confidence interval; OR, odds ratio.

Sensitivity, specificity and Youden's index at different age cut-off points.

Age Sensitivity 1-Specificity Youden's index
15 1 1 0.000
20 0.999 0.998 0.001
30 0.986 0.928 0.058
40 0.846 0.699 0.147
50 0.48 0.313 0.167
60 0.158 0.081 0.077
70 0.024 0.011 0.013
80 0.005 0.003 0.002

LR analysis of the risk of MetS associated with H. pylori infection in different groups.

H. pylori groups OR [95% CI] P-value
Males
  <50 years 1.28 [1.04–1.56] 0.017
  ≥50 years 1.21 [0.97–1.50] 0.088
Females
  <50 years 0.87 [0.58–1.30] 0.495
  ≥50 years 1.53 [1.10–2.10] 0.010

H. pylori, Helicobacter pylori; 95% CI, 95% confidence interval; OR, odds ratio.

Predictors of MetS by LR based on H. pylori infection and other factors.

Variables OR [95% CI] P-value
Age (years) 0.95 [0.68–0.98] <0.001
Sex 4.40 [4.27–6.97] <0.001
HS-CRP (mg/l) 1.94 [1.80–2.80] <0.001
ALT (U/l) 0.92 [0.85–0.99] <0.001
AST (U/l) 1.92 [1.19–3.15] <0.001
HbA1c (%) 1.51 [1.32–2.92] <0.001
Cr (mmol/l) 1.01 [1.39–1.80] 0.001
UA (µmol/l) 1.99 [1.59–3.49] <0.001
H. pylori infection 1.12 [1.02–1.59] 0.017

H. pylori, Helicobacter pylori; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HS-CRP, high-sensitivity C-reactive protein; HbA1c, glycosylated hemoglobin; Cr, creatinine; UA, uric acid; 95% CI, 95% confidence interval; OR, odds ratio.

Predictors of MetS by LR from subjects of sex groups with different ages.

Males Females
<50 years ≥50 years <50 years ≥50 years
Variables OR [95% CI] P-value OR [95% CI] P-value OR [95% CI] P-value OR [95% CI] P-value
HS-CRP (mg/l) 1.94 [1.9–1.99] 0.010 1.54 [1.49–1.59] 0.013 0.91 [0.81–1.03] 0.150 0.97 [0.92–1.03] 0.340
ALT (U/l) 1.89 [1.84–1.93] <0.001 0.96 [0.91–1.02] 0.180 1.80 [1.71–1.91] 0.003 1.01 [0.92–1.11] 0.890
AST (U/l) 2.07 [1.51–2.84] <0.001 1.62 [1.15–2.27] <0.001 5.53 [2.91–10.51] <0.001 1.15 [0.75–1.77] 0.520
HbA1c (%) 1.53 [1.44–1.64] <0.001 1.33 [1.26–1.62] <0.001 1.22 [1.12–1.39] <0.001 1.27 [1.19–1.4] <0.001
Cr (mmol/l) 1.02 [1.01–1.04] 0.001 1.00 [0.99–1.01] 0.800 1.06 [1.02–1.11] 0.007 1.01 [0.98–1.03] 0.700
UA (µmol/l) 1.10 [1.05–1.2] <0.001 1.09 [1.01–1.12] <0.001 1.02 [1.01–1.99] <0.001 1.05 [1.03–1.20] 0.003
H. pylori infection 0.82 [0.63–1.06] 0.130 0.79 [0.59–1.06] 0.120 1.39 [0.80–2.41] 0.250 1.29 [1.09–1.91] 0.002

H. pylori, Helicobacter pylori; MetS, metabolic syndrome; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HS-CRP, high-sensitivity C-reactive protein; HbA1c, glycosylated hemoglobin; Cr, creatinine; UA, uric acid; 95% CI, 95% confidence interval; OR, odds ratio.